Memery Crystal advise Curaleaf on UK aspects of landmark $285m acquisition

The acquisition is a huge milestone for the European cannabis market. The two leading companies combined, create a global platform that is poised to exploit the rapid pace of growth of the European cannabis market, especially in the potential shift from medical to more consumer-oriented.

Curaleaf are the most successful cannabis-based, consumer-oriented company in the U.S. In acquiring EMMAC, they have access to a wealth of local market experience, and supply and distribution partnerships throughout Europe. As consumer and political liberalisation trends increase, the winning combination of Curaleaf and EMMAC will undoubtedly create the largest operator on a revenue and a footprint basis around the globe.

The Memery Crystal team was led by our CEO and head of cannabis Nick Davis, and included corporate partner Kieran Stone, director Mark O’Donnell and solicitor Alex Heron. Employment support was provided by our head of employment Stephen Ravenscroft and senior associate Mark Rose.

Commenting on the transaction, Nick Davis said: “we are delighted to have advised Curaleaf on the UK aspects of this landmark acquisition.”

Cannabis is one of the world’s fastest-growing and most innovative industrial sectors. Led the by  CEO Nick Davis, Memery Crystal’s medicinal cannabis team are sector leaders within the UK, advising businesses on a broad range of issues. The practice includes business set-up, capital markets, mergers & acquisitions, private fundraising, licensing, and commercial contracts.